Cramer's Morning Take: Eli Lilly 4/30/24
Jim and Jeff discuss Eli Lilly after the company beat on quarterly profit and hiked its full-year guidance on strong sales of Mounjaro and Zepbound. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Jim and Jeff discuss Eli Lilly after the company beat on quarterly profit and hiked its full-year guidance on strong sales of Mounjaro and Zepbound. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake
CNBC Investing Club Disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.